Alexander Martin, OD
NPI 1851816201 · Optometrist · Brookline, MA
Enrolled with Medicare as Practitioner - Optometry · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1851816201
- Entity type
- Individual
- Primary specialty
- OptometristEye and Vision Services Providers
- Credential
- OD
- Sex
- Male
- Sole proprietor
- No
- License
- 0979 (NH)
Specialties & taxonomies
Eye and Vision Services Providers
Eye and Vision Services Providers
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
8 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
743 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Complete Exam of Visual System92014 | 292 | $128 |
| Established Patient Office Or Other Outpatient Visit With Low Level OD Decision Making, If Using Time, 20 Minutes Or More99213 | 277 | $94 |
| Photography of the Retina92250 | 49 | $38 |
| Imaging of Optic Nerve92133 | 43 | $36 |
| New Patient Complete Exam of Visual System92004 | 23 | $152 |
| Established Patient Problem Focused Exam of Visual System92012 | 23 | $92 |
| Imaging of Retina |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 18 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Cyclosporinebrand: Restasis | 206 | 85 |
| Latanoprost | 176 | 50 |
| Tobramycin/Dexamethasonebrand: Tobramycin-Dexamethasone | 95 | 75 |
| Prednisolone Acetate | 71 | 57 |
| Brinzolamide/Brimonidine Tartbrand: Simbrinza | 50 | 17 |
| Lifitegrastbrand: Xiidra | 49 | 21 |
| Loteprednol Etabonatebrand: Eysuvis | 42 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$801 across 31 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2017-08-07
- Last updated
- 2025-07-23
- Certified
- 2025-07-23
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.